Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin

British Journal of Clinical Pharmacology

Volumn 44, Issue 2, 1997, Pages 199-202

  Priskorn, M ^a   Sidhu, J S ^a   Larsen, F ^a   Davis, J D ^b   Khan, A Z ^b   Rolan, P E ^b  

^a H LUNDBECK A S   (Denmark)

^b Medeval Ltd   (United Kingdom)

Author keywords

(R) and (S) warfarin; Citalopram; Drug drug interaction; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CITALOPRAM; CYTOCHROME P450 ISOENZYME; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030876517     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00628.x     Document Type: Article

References (19)

1. Hyttel J. Pharmacological characterization of selective serotonin uptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9 supp.1: 19-26.
2. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983; 25: 610-620.
3. Eble JM, West BD, Link KP. A comparison of the isomers of warfarin. Biochem Pharmacol 1966; 15: 1003-1006.
4. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human CDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-59.
5. O'Reilly RA, Goulart DA, Kunze KL, et al. Mechanism of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992; 51: 656-667.
6. Øyehaug E, Østensen ET, Salvesen B. Determination of the antidepressant agent citalopram and metabolites in plasma by liquid chromatography with fluorescence detection. J Chromatogr 1982; 227: 129-135.
7. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151-159.
8. Sindrup SH, Brosen K, Hansen MGJ, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphism. Ther Drug Monitor 1993; 15: 11-17.
9. Quick AJ. Hemorrhagic diseases and thrombosis, Second Edition, Philadelphia: Lea & Fitbiger, 1966.
10. Banfield CR, Rowland M. Stereospecific fluorescence high performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharmacol Ther 1984; 73: 1392-1396.
11. Gibaldi M, Perrier D. Pharmacokinetics, Second Edition, New York: Marcel-Dekker, 1982.
12. Porter RS, Sawyer WT, Lowenthal DT. In Applied Pharmacokinetics, Second Edition (eds. Ewans WE, Shentag JJ, Jusko WJ), Spokane WA, Applied Therapeutics Inc, 1986 p. 1057-1104.
13. Toon S, Hopkins HJ, Garstang FM, et al. Enoxazin-warfarin interaction: Pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987; 42: 33-41.
14. Banfield CR, O'Reilly RA, Chan E, Rowland M. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983; 16: 669-675.
15. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereo-chemical considerations. J Pharm Sci 1986; 73: 1671-1673.
16. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203-220.
17. Bannister SH, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin and digoxin. Acta Psychiat Scand 1989; 80(suppl. 350): 102-106.
18. Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmaco- kinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313-334.
19. Rowe H, Carmichael R, Lemberger L. The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sciences 1978; 23: 807-811.